These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9350835)

  • 1. Growth/differentiation factor 5 protects nigrostriatal dopaminergic neurones in a rat model of Parkinson's disease.
    Sullivan AM; Opacka-Juffry J; Hötten G; Pohl J; Blunt SB
    Neurosci Lett; 1997 Sep; 233(2-3):73-6. PubMed ID: 9350835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroprotective effects of growth/differentiation factor 5 depend on the site of administration.
    Sullivan AM; Opacka-Juffry J; Pohl J; Blunt SB
    Brain Res; 1999 Feb; 818(1):176-9. PubMed ID: 9914454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo.
    Sullivan AM; Opacka-Juffry J; Blunt SB
    Eur J Neurosci; 1998 Jan; 10(1):57-63. PubMed ID: 9753113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of growth/differentiation factor 5 (GDF5) in the induction and survival of midbrain dopaminergic neurones: relevance to Parkinson's disease treatment.
    Sullivan AM; O'Keeffe GW
    J Anat; 2005 Sep; 207(3):219-26. PubMed ID: 16185246
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuroprotective effects of delayed administration of growth/differentiation factor-5 in the partial lesion model of Parkinson's disease.
    Hurley FM; Costello DJ; Sullivan AM
    Exp Neurol; 2004 Feb; 185(2):281-9. PubMed ID: 14736509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDNF protects against 6-OHDA nigrostriatal lesion: in vivo study with microdialysis and PET.
    Opacka-Juffry J; Ashworth S; Hume SP; Martin D; Brooks DJ; Blunt SB
    Neuroreport; 1995 Dec; 7(1):348-52. PubMed ID: 8742486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease.
    Sullivan AM; Pohl J; Blunt SB
    Eur J Neurosci; 1998 Dec; 10(12):3681-8. PubMed ID: 9875347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 6-Hydroxydopamine induces distinct alterations in GDF5 and GDNF mRNA expression in the rat nigrostriatal system in vivo.
    Gavin AM; Walsh S; Wyatt S; O'Keeffe GW; Sullivan AM
    Neurosci Lett; 2014 Feb; 561():176-81. PubMed ID: 24373993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroprotective activity of peripherally administered liver growth factor in a rat model of Parkinson's disease.
    Gonzalo-Gobernado R; Calatrava-Ferreras L; Reimers D; Herranz AS; Rodríguez-Serrano M; Miranda C; Jiménez-Escrig A; Díaz-Gil JJ; Bazán E
    PLoS One; 2013; 8(7):e67771. PubMed ID: 23861803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trophic and protective effects of growth/differentiation factor 5, a member of the transforming growth factor-beta superfamily, on midbrain dopaminergic neurons.
    Krieglstein K; Suter-Crazzolara C; Hötten G; Pohl J; Unsicker K
    J Neurosci Res; 1995 Dec; 42(5):724-32. PubMed ID: 8600306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nerve growth factor increases survival of dopaminergic graft, rescue nigral dopaminergic neurons and restores functional deficits in rat model of Parkinson's disease.
    Chaturvedi RK; Shukla S; Seth K; Agrawal AK
    Neurosci Lett; 2006 May; 398(1-2):44-9. PubMed ID: 16423459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Riluzole neuroprotection in a Parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation.
    Carbone M; Duty S; Rattray M
    BMC Neurosci; 2012 Apr; 13():38. PubMed ID: 22480308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of growth/differentiation factor 5 on the survival and morphology of embryonic rat midbrain dopaminergic neurones in vitro.
    O'Keeffe GW; Dockery P; Sullivan AM
    J Neurocytol; 2004 Sep; 33(5):479-88. PubMed ID: 15906156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of GDF5 on the medial and lateral rat ventral mesencephalon.
    Clayton KB; Sullivan AM
    Neurosci Lett; 2007 Nov; 427(3):132-7. PubMed ID: 17935884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopaminergic neuroprotection and regeneration by neurturin assessed by using behavioral, biochemical and histochemical measurements in a model of progressive Parkinson's disease.
    Oiwa Y; Yoshimura R; Nakai K; Itakura T
    Brain Res; 2002 Aug; 947(2):271-83. PubMed ID: 12176170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heparin-binding epidermal growth factor-like growth factor: a component in chromaffin granules which promotes the survival of nigrostriatal dopaminergic neurones in vitro and in vivo.
    Hanke M; Farkas LM; Jakob M; Ries R; Pohl J; Sullivan AM
    Neuroscience; 2004; 124(4):757-66. PubMed ID: 15026116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
    Matsuura K; Makino H; Ogawa N
    Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.